Compare Stocks

→ The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$20.44 -0.9%	$24.72	$9.41 ▼ $32.42	$570.28M	1.4	130,327 shs	142,514 shs
CMPS COMPASS Pathways	$8.54 -0.8%	$9.51	$5.01 ▼ $12.75	$528.97M	2.39	660,015 shs	483,744 shs
MLTX MoonLake Immunotherapeutics	$43.66 -1.9%	$46.54	$24.31 ▼ $64.98	$2.79B	1.29	443,597 shs	302,513 shs
VERU Veru	$1.63 -0.6%	$0.96	$0.36 ▼ $1.92	$238.60M	-0.47	2.40 million shs	2.09 million shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+1.63%	+0.34%	-17.68%	+3.25%	-6.32%
CMPS COMPASS Pathways	+0.94%	+6.17%	-9.37%	-18.16%	+7.09%
MLTX MoonLake Immunotherapeutics	-1.63%	+6.58%	-5.62%	-24.01%	+65.44%
VERU Veru	+0.61%	+31.20%	+77.28%	+272.14%	+22.39%

The 2024 Gold Rush: Unleashing Market Potential (Ad)

Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.

Get your free information kit NOW, before it's too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
AVTE Aerovate Therapeutics	1.0636 of 5 stars	3.5	1.0	1.7	1.7
CMPS COMPASS Pathways	1.1031 of 5 stars	3.5	1.0	1.8	1.7
MLTX MoonLake Immunotherapeutics	2.3145 of 5 stars	4.4	2.0	0.0	3.3
VERU Veru	1.1388 of 5 stars	3.4	1.0	2.4	1.7

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	3.00	Buy	$49.33	141.36% Upside
CMPS COMPASS Pathways	3.00	Buy	$47.40	455.04% Upside
MLTX MoonLake Immunotherapeutics	2.75	Moderate Buy	$74.46	70.55% Upside
VERU Veru	2.75	Moderate Buy	$3.67	124.95% Upside

Current Analyst Ratings

Latest CMPS, AVTE, MLTX, and VERU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/6/2024	VERU Veru	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$2.00 ➝ $3.00
4/30/2024	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
4/23/2024	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
4/18/2024	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
4/15/2024	VERU Veru	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $5.00
4/11/2024	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
4/9/2024	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00
4/4/2024	AVTE Aerovate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/2/2024	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$62.00
4/1/2024	AVTE Aerovate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$35.00
4/1/2024	CMPS COMPASS Pathways	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$30.00

(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A
VERU Veru	$16.30M	14.64	N/A	N/A	$0.22 per share	7.41

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$2.88	N/A	N/A	N/A	N/A	-61.62%	-55.08%	5/20/2024 (Estimated)
CMPS COMPASS Pathways	-$118.46M	-$2.39	N/A	N/A	N/A	N/A	-58.72%	-49.46%	5/8/2024 (Confirmed)
MLTX MoonLake Immunotherapeutics	-$36.01M	-$0.76	N/A	N/A	N/A	N/A	-9.22%	-9.00%	5/10/2024 (Estimated)
VERU Veru	-$93.15M	-$0.75	N/A	N/A	N/A	-405.04%	-257.92%	-107.27%	5/8/2024 (Confirmed)

Latest CMPS, AVTE, MLTX, and VERU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2024	N/A	CMPS COMPASS Pathways	-$0.52	N/A	+$0.52	N/A	N/A	N/A
5/8/2024	N/A	VERU Veru	-$0.06	N/A	+$0.06	N/A	N/A	N/A
5/7/2024	N/A	MLTX MoonLake Immunotherapeutics	-$0.19	-$0.22	-$0.03	N/A	N/A	N/A
4/1/2024	Q1 2024	VERU Veru	N/A	-$0.09	-$0.09	-$0.10	N/A	$2.14 million
3/25/2024	Q4 2023	AVTE Aerovate Therapeutics	-$0.68	-$0.74	-$0.06	-$0.74	N/A	N/A
2/29/2024	Q4 2023	CMPS COMPASS Pathways	-$0.37	-$0.53	-$0.16	-$0.53	N/A	N/A
2/29/2024	Q4 2023	MLTX MoonLake Immunotherapeutics	-$0.23	-$0.12	+$0.11	-$0.12	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	7.04	7.04
CMPS COMPASS Pathways	0.14	13.33	13.33
MLTX MoonLake Immunotherapeutics	N/A	51.59	51.59
VERU Veru	N/A	3.21	2.79

Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
CMPS COMPASS Pathways	46.19%
MLTX MoonLake Immunotherapeutics	93.85%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	19.30%
CMPS COMPASS Pathways	4.25%
MLTX MoonLake Immunotherapeutics	15.27%
VERU Veru	14.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	51	27.90 million	22.52 million	Optionable
CMPS COMPASS Pathways	186	61.94 million	59.31 million	Optionable
MLTX MoonLake Immunotherapeutics	50	63.89 million	56.21 million	Optionable
VERU Veru	189	146.38 million	125.60 million	Optionable

CMPS, AVTE, MLTX, and VERU Headlines

Source	Headline
	Veru Q2 2024 Earnings Preview msn.com - May 7 at 5:55 PM
	Critical Insights From Veru Analyst Ratings: What You Need To Know benzinga.com - May 6 at 6:40 PM
	HC Wainwright Boosts Veru (NASDAQ:VERU) Price Target to $3.00 marketbeat.com - May 6 at 8:47 AM
	Analysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS) markets.businessinsider.com - May 3 at 11:46 PM
	Veru (VERU) to Release Quarterly Earnings on Wednesday marketbeat.com - May 2 at 9:59 AM
	Veru to Present at the GLP-1 Based Therapeutics Summit globenewswire.com - May 2 at 8:30 AM
	Hospitals inquiry concluded, 78 boxes of evidence passed on to Attorney General maltatoday.com.mt - May 1 at 9:06 AM
	Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 globenewswire.com - May 1 at 8:30 AM
	Veru (NASDAQ:VERU) Share Price Passes Above Two Hundred Day Moving Average of $0.78 americanbankingnews.com - May 1 at 3:30 AM
	Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy? zacks.com - April 30 at 10:56 AM
	Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss globenewswire.com - April 30 at 8:30 AM
	Palisade Capital Management Welcomes Chris Mashia to Small Cap Core and Smid Cap Core Equity Strategies finance.yahoo.com - April 30 at 12:33 AM
	Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 globenewswire.com - April 25 at 8:30 AM
	Netflix To Stop Sharing Subscriber Data; Stock Dips markets.businessinsider.com - April 19 at 6:13 PM
	What Makes Veru (VERU) a New Buy Stock zacks.com - April 17 at 1:01 PM
	Veru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimer marketbeat.com - April 15 at 8:29 AM
	REVEALED: Transport Malta officials at centre of maritime fines corruption racket maltatoday.com.mt - April 2 at 12:43 AM
	Veru Announces Date of 2024 Annual Meeting of Shareholders finance.yahoo.com - April 1 at 7:43 PM
	Flag carrier Air Malta ceases operations today, its 50th birthday maltatoday.com.mt - March 31 at 6:39 PM
	Veru Inc morningstar.com - March 29 at 9:35 PM
	Updated \| Mosta trees vandalised: ERA, police investigating maltatoday.com.mt - March 29 at 8:54 AM
	R&B Realty’s Gateway at Wynwood hit with foreclosure lawsuit therealdeal.com - March 22 at 6:18 PM
	Veru Reschedules Annual Meeting of Shareholders globenewswire.com - March 22 at 4:05 PM
	Wynwood offices targeted in $102M foreclosure bizjournals.com - March 21 at 6:43 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aerovate Therapeutics

NASDAQ:AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

COMPASS Pathways

NASDAQ:CMPS

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

MoonLake Immunotherapeutics

NASDAQ:MLTX

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Veru

NASDAQ:VERU

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial